A comprehensive review of spinocerebellar ataxia type 2 in Cuba

Cerebellum

Volumn 10, Issue 2, 2011, Pages 184-198

  Velázquez Pérez, Luis ^a   Rodríguez Labrada, Roberto ^a   García Rodríguez, Julio Cesar ^b   Almaguer Mederos, Luis Enrique ^a   Cruz Mariño, Tania ^a   Laffita Mesa, José Miguel ^a  

^a Centro Para la Investigación y Rehabilitación de Ataxias Hereditarias   (Cuba)

^b Centro Nacional para la Producción de Animales de Laboratorio CENPALAB   (Cuba)

Author keywords

Cerebellar ataxia; Cerebellar syndrome; Spinocerebellar ataxia

Indexed keywords

ATAXIN 2; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYSTEINE PROTEINASE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; LITHIUM; MAGNESIUM; PLACEBO; RILUZOLE; UNCLASSIFIED DRUG; VITAMIN B COMPLEX; ZINC;

ATXN2 GENE; BRADYKINESIA; BRAIN DEPTH STIMULATION; CAG REPEAT; CEREBELLAR ATAXIA; CUBA; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MEGADOSE; DYSTONIA; ELECTROMYOGRAPHY; EVOKED RESPONSE; EYE MOVEMENT DISORDER; GENE; GENE EXPRESSION; GENETIC COUNSELING; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; MOLECULAR DYNAMICS; MOTOR NEURON DISEASE; MUSCLE CRAMP; NERVE CONDUCTION; NEUROPATHY; NONHUMAN; ONSET AGE; PHENOTYPIC VARIATION; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOLOGIC ASSESSMENT; REHABILITATION CARE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SMELLING DISORDER; SPINOCEREBELLAR DEGENERATION; SPINOCEREBELLAR DEGENERATION TYPE 2; UNSPECIFIED SIDE EFFECT;

ANIMALS; CUBA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; PHENOTYPE; SPINOCEREBELLAR ATAXIAS;

EID: 80051800168     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-011-0265-2     Document Type: Review

References (109)

1. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885-94.
2. Matilla A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129:1357-70. (Pubitemid 43999370)
3. Paulson HL. The spinocerebellar ataxias. J Neuroophthalmol. 2009;29(3):227-37.
4. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet. 2004;3:291-304. (Pubitemid 38510200)
5. Wadia NH, Swami RK. A new form of heredo-familial spinocerebellar degeneration with slow eye movements (nine families). Brain. 1971;94:359-74.
6. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285-91.
7. Pulst MS, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14:269-76.
8. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet. 1996;14:277-84.
9. Velázquez Pérez L, Cruz GS, Santos Falcón N, Almaguer Mederos L, Escalona Batallan K, Rodriguez Labrada R, et al. Molecular epidemiology of spinocerebellar ataxias in Cuba: insights into SCA2 founder effect in Holguin. Neurosci Lett. 2009;454(2):157-60.
10. Vallés L, Estrada GL, Bastecherrea SL. Algunas formas de heredoataxia en una región de Cuba. Rev Neurol (Cubana). 1978;27:163-76.
11. Velázquez-Pérez L, Santos FN, García R, Paneque HM, Hechavarría PR. Epidemiología de la Ataxia Cubana. Rev Neurol. 2001;32(7):606-11.
12. Orozco DG, Estrada R, Perry T, Araña J, Fernández R. Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological and biochemical findings. J Neurol Sci. 1989;93:37-50. (Pubitemid 19244006)
13. Gispert S, Twells R, Orozco G, Brice A, Weber J, Heredero L, et al. Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet. 1993;4:295-9. (Pubitemid 23205180)
14. Hernandez A, Magarino C, Gispert S, Santos N, Lunkes A, Orozco G, et al. Genetic mapping of the spinocerebellar ataxia 2 (SCA2) locus on chromosome 12q23-q24.1. Genomics. 1995;25:433-5.
15. Aguiar J, Fernández J, Aguilar A, Mendoza Y, Vázquez M, Suárez J, et al. Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett. 2006;392:202-6. (Pubitemid 41739625)
16. Paneque HM, Prieto AL, Reynaldo RR, Cruz MT, Santos FN, Almaguer ML, et al. Psychological aspects of presymptomatic diagnosis of spinocerebellar ataxia type 2 in Cuba. Community Genet. 2007;10:132-9. (Pubitemid 46944288)
17. Paneque M, Lemos C, Escalona K, Prieto L, Reynaldo R, Velazquez M, et al. Psychological follow-up of presymptomatic genetic testing for spinocerebellar ataxia type 2 (SCA2) in Cuba. J Genet Couns. 2007;16:469-79. (Pubitemid 47305503)
18. Paneque M, Lemos C, Sousa A, Velazquez L, Fleming M, Sequeiros J. Role of the disease in the psychological impact of pre-symptomatic testing for SCA2 and FAP ATTRV30M: experience with the disease, kinship and gender of the transmitting parent. J Genet Couns. 2009;18:483-93.
19. Sequeiros J, Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol. 1993;61:139-53.
20. Vale J, Bugalho P, Silveira I, Sequeiros J, Guimaraes J, Coutinho P. Autosomal dominant cerebellar ataxia: frequency analysis and clinical characterization of 45 families from Portugal. Eur J Neurol. 2010;17:124-8.
21. Klockgether T. Ataxias. In: Goetz CG, editor. Textbook of clinical neurology, vol 1. Toronto: Saunder; 2007. p. 741-57.
22. Alonso E, Martinez-Ruano L, De Biase I, Mader C, Ochoa A, Yescas P, et al. Distinct distribution of autosomal dominant spinocerebellar ataxia in the Mexican population. Mov Disord. 2007;22:1050-3. (Pubitemid 46999310)
23. Sułek-Piatkowska A, Zdzienicka E, Raczyńska-Rakowicz M, Krysa W, Rajkiewicz M, Szirkowiec, et al. The occurrence of spinocerebellar ataxias caused by dynamic mutations in Polish patients. J Neurol Neurochir Pol. 2010;44(3):238-45.
24. Takano H, Cancel G, Ikeuchi T, Lorenzetti D, Mawad R, Stevanin G, et al. Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. Am J Hum Genet. 1998;63:1060-6. (Pubitemid 30418575)
25. Parduey M. The pathogenesis of Machado Joseph disease: a high manganese/low magnesium initiated CAG expansion mutation in susceptible genotypes? J Am Coll Nutr. 2004;23:715S-29.
26. Berciano J. Olivopontocerebellar atrophy. In: Gilman S, editor. Neurobiology of the disease. California: Elsevier; 2007. p. 95-104.
27. Schols L, Haan J, Riess O, Amoiridis G, Przuntek H. Sleep disturbance in spinocerebellar ataxias: is the SCA 3 mutation a cause of restless legs syndrome? Neurology. 1998;51:1603-7.
28. Irazno A, Comella CL, Santamaria J, Oertel W. Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Mov Disord. 2007;22: S424-30.
29. Abele M, Burk K, Laccone F, Dichgans J, Klockgether T. Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. J Neurol. 2001;248(4):311-4. (Pubitemid 32323870)
30. Burk K, Globas C, Bosch S, Klockgether T, Zuhlke C, Daum I, et al. Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J Neurol. 2003;250:207-11. (Pubitemid 36223096)
31. Reynaldo-Arminan RD, Reynaldo-Hernandez R, Paneque-Herrera M, Prieto-Avila L, Perez-Ruiz E. Mental disorders in patients with spinocerebellar ataxia type 2 in Cuba. Rev Neurol. 2002;35:818-21. (Pubitemid 35447188)
32. Storey E, Forrest SM, Shaw JH, Mitchell P, Gardner RJ. Spinocerebellar ataxia type 2: clinical features of a pedigree displaying prominent frontal-executive dysfunction. Arch Neurol. 1999;56:43-50. (Pubitemid 29046908)
33. Le Pira F, Zappala G, Saponara R, Domina E, Restivo D, Reggio E, et al. Cognitive findings in spinocerebellar ataxia type 2: relationship to genetic and clinical variables. J Neurol Sci. 2002;201:53-7. (Pubitemid 34876905)
34. Babovic-Vuksanovic D, Snow K, Patterson MC, Michels VV. Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion. Am J Med Genet. 1998;79:383-7. (Pubitemid 28445450)
35. Rufa A, Dotti MT, Galli L, Orrico A, Sicurelli F, Federico A. Spinocerebellar ataxia type 2 (SCA2) associated with retinal pigmentary degeneration. Eur Neurol. 2002;47:128-9. (Pubitemid 34161170)
36. Tan NC, Zhou Y, Tan AS, Chong SS, Lee WL. Spinocerebellar ataxia type 2 with focal epilepsy-an unusual association. Ann Acad Med Singapore. 2004;33:103-6. (Pubitemid 38478121)
37. Lu CS, Wu Chou YH, Kuo PC, Chang HC, Weng YH. The parkinsonian phenotype of spinocerebellar ataxia type 2. Arch Neurol. 2004;61:35-8.
38. Charles P, Camuzat A, Benammar N, Sellal F, Destée A, Bonnet AM. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology. 2007;69:1970-5. (Pubitemid 350145088)
39. Klockgether T, Ludtke R, Kramer B, AbeleM, Burk K, Schols L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;121(Pt 4):589-600. (Pubitemid 28162122)
40. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717-20. (Pubitemid 43964628)
41. Schmitz-Hubsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;271 (13):982-9.
42. Giunti P, Sabbadini G, Sweeney MG, Davis MB, Veneziano L, Mantuano E, et al. The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlates. Brain. 1998;121 (Pt 3):459-67. (Pubitemid 28116343)
43. Ying SH, Choi SI, Perlman SL, Baloh RW, Zee DS, Toga AW. Pontine and cerebellar atrophy correlate with clinical disability in SCA2. Neurology. 2006;66(3):424-6. (Pubitemid 43739950)
44. Estrada R, Galarraga J, Orozco G, Nodarse A, Auburger G. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol. 1999;97:306-10. (Pubitemid 29137281)
45. Cancel G, Durr A, Didierjean O, Imbert G, Burk K, Lezin A, et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet. 1997;6:709-15. (Pubitemid 27199064)
46. Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Pulst SM. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet. 1997;60:842-50. (Pubitemid 27146492)
47. Almaguer-Mederos LE, Falcon NS, Almira YR, Zaldivar YG, Almarales DC, Gongora EM, et al. Estimation of the age at onset in spinocerebellar ataxia type 2 Cuban patients by survival analysis. Clin Genet. 2010;78:169-74.
48. Shibata H, Huynh DP, Pulst SM. A novel protein with RNAbinding motifs interacts with ataxin-2. Hum Mol Genet. 2000;9:1303-13. (Pubitemid 30312479)
49. Satterfield TF, Pallanck LJ. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet. 2006;15:2523-32. (Pubitemid 44288704)
50. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell. 2007;18:1385-96. (Pubitemid 46626633)
51. Satterfield TF, Jackson SM, Pallanck LJ. A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics. 2002;162:1687-702. (Pubitemid 36114656)
52. Ralser M, Nonhoff U, Albrecht M, Lengauer T, Wanker EE, et al. Ataxin-2 and Huntington interact with endophilin-A complexes to function in plastin-associated pathways. Hum Mol Genet. 2005;14:2893-909. (Pubitemid 41418794)
53. Kiehl TR, Nechiporuk A, Figueroa KP. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun. 2006;339:17-24. (Pubitemid 41697509)
54. Lastres-Becker I, Brodesser S, Lütjohann D, Azizov M, Buchmann J, Hintermann E, et al. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum Mol Genet. 2008;17(10):1465-81. (Pubitemid 351627343)
55. Matilla-Dueñas A, Sánchez I, Corral-Juan M, Dávalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9(2):148-66.
56. Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci. 2009;29(29):9148-62.
57. Kasumu A, Bezprozvanny I. Deranged calcium signaling in purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias. Cerebellum. 2010. doi:10.1007/s12311-010-0182-9.
58. Pulst SM, Santos N, Wang D, Yang H, Huynh D, et al. Spinocerebellar ataxia type 2: PolyQ repeat variation in the CACNA1A channel modifies age of onset. Brain. 2005;128:2297-303. (Pubitemid 41407970)
59. Simon DK, Zheng K, Velazquez L, Figueroa KP, Falcon N, Almaguer, et al. Mithochondrial complex I gene variant associated with early age of onset in SCA2. Arch Neurol. 2007;64:1042-4. (Pubitemid 47048008)
60. Hayes S, Turecki G, Brisebois K, Lopes-Cendes I, Gaspar C, Riess O, et al. CAG repeat length in RAI1 is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2). Hum Mol Genet. 2000;9(12):1753-8. (Pubitemid 30608609)
61. Pulst SM. Spinocerebellar ataxia type 2. In: Wells RD, Ashizhawa T, editors. Genetic instabilities and neurological diseases. California: Elsevier; 2006. p. 351-61.
62. González C, Sánchez G, González Quevedo A, Delgado R, Velásquez L, García Rodriguez JC, et al. Serum and cerebrospinal fluid levels of copper, iron and zinc in patients with ataxia type SCA-2 from the province of Holguin in Cuba. Therapeutic basic. Dialog Clin Neurosci. 2005;13(4):12-6.
63. Almaguer L, Almaguer D, Gonzáles Y, Martinez E, Valcárcel P. Capacidad antioxidante total de en pacientes cubanos con ataxia Espinocerebelosa tipo 2. Rev Mex Neuroci. 2005;6(3):201-6.
64. Velázquez L, Sánchez G, García JC, Delgado R, Márquez L, Martínez E, et al. Spinocerebellar ataxia type 2 (sca-2) in Cuba. A study of the clinical electrophysiological and redox system variations and its correlation with CAG repeats. Rest Neurol Neurosci. 2003;20(6):277.
65. Abele M, Schols L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in ataxia patients.Neurology. 2003;60:1674-5. (Pubitemid 36618099)
66. Bushara KO, Nance M, Gomez CM. Antigliadin antibodies in Huntington disease. Neurology. 2004;62:132-3.
67. Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallet M. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol. 2001;49:540-3. (Pubitemid 32281342)
68. Almaguer-Mederos LE, Almira YR, Góngora EM, Gotay DA, Zaldivar YG, Pupo RE, et al. Antigliadin antibodies in Cuban patients with spinocerebellar ataxia type 2. J Neurol Neurosurg Psychiatry. 2008;79:315-7. (Pubitemid 351303391)
69. Chinnery PF, Reading PJ, Milne D, Gardner-Medwin D, Turnbull DM. CSF antigliadin antibodies and the Ramsay Hunt syndrome. Neurology. 1997;49:1131-3. (Pubitemid 27456099)
70. Gierga K, Burk K, Bauer M, Orozco Diaz G, Auburger G, Schultz C, et al. Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathol. 2005;109:617-31. (Pubitemid 40974151)
71. Hoche F, Seidel K, Brunt ER, Auburger G, Schols L, Burk K, et al. Involvement of the auditory brainstem system in spinocerebellar ataxia type 2 (SCA2), type 3 (SCA3) and type 7 (SCA7). Neuropathol Appl Neurobiol. 2008;34:479-91.
72. Rub U, Del Turco D, Burk K, Diaz GO, Auburger G, Mittelbronn M, et al. Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. Neuropathol Appl Neurobiol. 2005;31:127-40. (Pubitemid 40444914)
73. Rub U, Seidel K, Ozerden I, Gierga K, Brunt ER, Schols L, et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev. 2007;53:235-49. (Pubitemid 46177231)
74. Velazquez Perez L, Sanchez Cruz G, Canales Ochoa N, Rodriguez Labrada R, Rodriguez Diaz J, Almaguer Mederos L, et al. Electrophysiological features in patients and presymptomatic relatives with spinocerebellar ataxia type 2. J Neurol Sci. 2007;263:158-64. (Pubitemid 350029861)
75. Velazquez-Perez L, Rodriguez-Labrada R, Canales-Ochoa N, Sanchez-Cruz G, Fernandez-Ruiz J, Montero JM, et al. Progression markers of spinocerebellar ataxia 2. A twenty years neurophysiological follow up study. J Neurol Sci. 2010;290:22-6.
76. Kremlacek J, Valis M, Masopust J, Talab R, Kuba M, Kobova Z, et al. Electrophysiological study of visual processing in spinocerebellar ataxia type 2 (SCA2). Cerebellum. 2010. doi:10.1007/s12311-010-0220-7.
77. Velazquez-Perez L, Rodriguez-Labrada R, Medrano-Montero J, Sanchez-Cruz G, Canales-Ochoa N, Torres-Parra C, et al. Electromyographic pattern in patients and asymptomatic carriers of the SCA2 mutation. Rev Neurol. 2009;49:55-6.
78. Elden AC, Kim HJ, Hart HP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069-75.
79. Tuin I, Voss U, Kang JS, Kessler K, Rub U, Nolte D, et al. Stages of sleep pathology in spinocerebellar ataxia type 2 (SCA2). Neurology. 2006;67:1966-72. (Pubitemid 44967372)
80. Boesch SM, Frauscher B, Brandauer E, Wenning GK, Hogl B, Poewe W. Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2. Mov Disord. 2006;21:1751-4. (Pubitemid 44742213)
81. Rodriguez-Labrada R, Velazquez-Pérez L, Canales-Ochoa N, Galicia-Polo L, Haro-Valencia R, Sánchez-Cruz G, et al. Subtle REM sleep abnormalities in presymptomatic spinocerebellar ataxia type 2 gene carriers. Mov Disord. 2010. doi:10.1002/mds.23409.
82. Velazquez-Perez L, Seifried C, Santos-Falcon N, Abele M, Ziemann U, Almaguer LE, et al. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol. 2004;56:444-7. (Pubitemid 39166568)
83. Seifried C, Velazquez-Perez L, Santos-Falcon N, Abele M, Ziemann U, Almaguer LE, et al. Saccade velocity as a surrogate disease marker in spinocerebellar ataxia type 2. Ann N Y Acad Sci. 2005;1039:524-7. (Pubitemid 40979919)
84. Geiner S, Horn AK, Wadia NH, Sakai H, Buttner-Ennever JA. The neuroanatomical basis of slow saccades in spinocerebellar ataxia type 2 (Wadia-subtype). Prog Brain Res. 2008;171:575-81.
85. Velazquez-Perez L, Seifried C, Abele M, Wirjatijasa F, Rodriguez-Labrada R, Santos-Falcon N, et al. Saccade velocity is reduced in presymptomatic spinocerebellar ataxia type 2. Clin Neurophysiol. 2009;120:632-5.
86. Buttner N, Geschwind D, Jen JC, Perlman S, Pulst SM, Baloh RW. Oculomotor phenotypes in autosomal dominant ataxias. Arch Neurol. 1998;55(10):1353-7. (Pubitemid 28465871)
87. Burk K, Fetter M, Abele M, Laccone F, Brice A, Dichgans J, et al. Autosomal dominant cerebellar ataxia type I: oculomotor abnormalities in families with SCA1, SCA2, and SCA3. J Neurol. 1999;246:789-97. (Pubitemid 29467154)
88. Connelly T, Farmer JM, Lynch DR, Doty RL. Olfactory dysfunction in degenerative ataxias. J Neurol Neurosurg Psychiatry. 2003;74:1435-7.
89. Fernandez-Ruiz J, Diaz R, Hall-Haro C, Vergara P, Fiorentini A, Nunez L, et al. Olfactory dysfunction in hereditary ataxia and basal ganglia disorders. Neuroreport. 2003;14:1339-41. (Pubitemid 36936721)
90. Velazquez-Perez L, Fernandez-Ruiz J, Diaz R, Gonzalez RP, Ochoa NC, Cruz GS, et al. Spinocerebellar ataxia type 2 olfactory impairment shows a pattern similar to other major neurodegenerative diseases. J Neurol. 2006;253:1165-9. (Pubitemid 44511473)
91. Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet. 2000;26:44-50.
92. European Community Huntington Disease Collaborative Study Group: ethical and social issues in presymptomatic testing for Huntington's disease. A European Community collaborative study. J Med Genet. 1993;1028-35.
93. Harper PS, Newcombe RG. Age at onset and life table risks in genetic counselling for Huntington's disease. J Med Genet. 1992;29(4):239-42.
94. Sequeiros J. Machado-Joseph disease: epidemiology, genetics and genetic epidemiology. In: Lechtenberg R, editor. Handbook of cerebellar diseases. New York: Dekker; 1993. p. 345-51.
95. Almaguer-Mederos LE, Proenza CL, Rodríguez Almira Y, Escalona Batallán K, Santos Falcón N, Martínez Góngora E, et al. Age-dependent risks in genetic counseling for spinocerebellar ataxia type 2. Clin Genet. 2008;74:571-3.
96. Chai Y, Wu L, Griffin JD, Paulson HL. The role of protein composition in specifying nuclear inclusion formation in polyglutamine diseases. J Biol Chem. 2001;276(48):44889-97.
97. Nozaki K, Onodera O, Takano H, Tsuji S. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation. Neuroreport. 2001;12 (15):3357-64. (Pubitemid 33010672)
98. Leznicki P. Aggregation and toxicity of the proteins with polyQ repeats. Postepy Biochem. 2005;51(2):215-22.
99. Adam S, Wiggins S, Whyte P, Bloch M, Shokeir MHK, Soltan H, et al. Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment. J Med Genet. 1993;30:549-56. (Pubitemid 23225179)
100. Quaid KA. Presymptomatic testing for Huntington disease in the United States. Am J Hum Genet. 1993;53:785-7. (Pubitemid 23304155)
101. Underwood BR, Rubinsztein DC. Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. Cerebellum. 2008;7:215-21.
102. Perez-Avila I, Fernandez-Vieitez JA, Martinez-Gongora E, Ochoa-Mastrapa R, Velazquez-Manresa MG. Effects of a physical training program on quantitative neurological indices in mild stage type 2 spinocerebellar ataxia patients. Rev Neurol. 2004;39:907-10. (Pubitemid 39643529)
103. Rodríguez JC, Velázquez L, Sánchez G, Almaguer L, Almaguer D, García JC, et al. Evaluación de la restauración neurológica en pacientes con ataxia SCA2 cubana. Plast & Rest Neurol. 2008;7 (1):13-8.
104. Pirker W, Back C, Gerschlager W, Laccone F, Alesch F. Chronic thalamic stimulation in a patient with spinocerebellar ataxia type 2. Mov Disord. 2003;18:222-5.
105. Freund HJ, Barnikol UB, Nolte D, Treuer H, Auburger G, Tass PA, et al. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. Mov Disord. 2007;22:732-5. (Pubitemid 46800150)
106. Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial (CME) (LOE Classification). Neurology. 2010;74(10):839-45.
107. Takei A, Hamada S, Homma S, Hamada K, Tashiro K, Hamada T. Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. Cerebellum. 2010. doi:10.1007/s12311-010- 0199-0.
108. Manconi M, Ferri R, Feroah TR, Zucconi M, Ferini-Strambi L. Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist. Sleep. 2008;31(9):1229-37.
109. Vetrugno R, D'Angelo R, Montagna P. Periodic limb movements in sleep and periodic limb movement disorder. Neurol Sci. 2007;28:S9-14.